Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective

Choy, Ernest; Richards, Selwyn; Bowrin, Kevin; Watson, P.; Lloyd, Adam; Sadosky, Alesia; Zlateva, Gergana

doi:10.1185/03007991003600271

Cited by 19 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Amitriptyline, a tricyclic antidepressant, also has undergone traditional study in the treatment of a wide variety of painful conditions, including MPS [22‐36]. Nortriptyline is a second‐generation tricyclic antidepressant with less incidence of adverse effects compared with amitriptyline.…”

Section: Medicationsmentioning

confidence: 99%

Emerging Concepts in the Treatment of Myofascial Pain: A Review of Medications, Modalities, and Needle‐based Interventions

Annaswamy

Luigi

O’Neill

et al. 2011

PM&R

View full text Add to dashboard Cite

Significant developments and changes in the use of interventions and treatments for the management of myofascial pain syndrome have occurred in the past 10 years. These emerging concepts have changed the approach for clinicians who manage these pain disorders. However, wide variations in practice patterns prevail, and no clear consensus exists regarding when and how to use these interventions; in addition, awareness of the evidence basis behind their use is limited. This review examines the most recent advances in the treatment of myofascial pain syndromes. Specifically, the evidence basis of various emerging interventions is reviewed and recommendations for routine clinical practice and their rationale are provided. The purpose of this review is to provide the clinician with a better understanding of emerging concepts in the interventions used for myofascial pain syndromes.

show abstract

Section: Medicationsmentioning

confidence: 99%

Emerging Concepts in the Treatment of Myofascial Pain: A Review of Medications, Modalities, and Needle‐based Interventions

Annaswamy

Luigi

O’Neill

et al. 2011

PM&R

View full text Add to dashboard Cite

show abstract

“…However, the effectiveness of these interventions showed conflicting results [12, 13]. In the absence of substantial clinical effects, the cost-effectiveness of interventions in FM is disappointing [14–16]. The importance of a prompt (and earlier) diagnosis and of immediate (intensive) intervention are increasingly discussed as potential opportunities to prevent the development of persistent pain and long-term dysfunction and therefore might increase effectiveness of interventions [13, 17, 18].…”

Section: Introductionmentioning

confidence: 99%

Resource utilisation and direct costs in patients with recently diagnosed fibromyalgia who are offered one of three different interventions in a randomised pragmatic trial

et al. 2015

View full text Add to dashboard Cite

The purpose of this study is to understand the course of costs over a 2-year period in a cohort of recently diagnosed fibromyalgia (FM) patients receiving different treatment strategies. Following the diagnosis, patients were randomly assigned to a multidisciplinary programme (MD), aerobic exercise (AE) or usual care (UC) without being aware of alternative interventions. Time between diagnosis and start of treatment varied between patients. Resource utilisation, health care costs and costs for patients and families were collected through cost diaries. Mixed linear model analyses (MLM) examined the course of costs over time. Linear regression was used to explore predictors of health care costs in the post-intervention period. Two hundred three participants, 90 % women, mean (SD) age 41.7 (9.8) years, were included in the cohort. Intervention costs per patient varied from €864 to 1392 for MD and were €121 for AE. Health care costs (excluding intervention costs) decreased after diagnosis, but before the intervention in each group, and increased again afterwards to the level close to the diagnostic phase. In contrast, patient and family costs slightly increased over time in all groups without initial decrease immediately after diagnosis. Annualised health care costs post-intervention varied between €1872 and 2310 per patient and were predicted by worse functioning and high health care costs at diagnosis. In patients with FM, health care costs decreased following the diagnosis by a rheumatologist. Offering patients a specific intervention after diagnosis incurred substantial costs while having only marginal effects on costs.

show abstract

“…Another study conducted in the UK found that pregabalin was cost-effective to the UK National Health Service where effectiveness was measured with qualityadjusted life years (QALY) based on a patient's utility gain from treatment response. The incremental cost-effectiveness ratio (ICER) in that study was £23,166/QALY for pregabalin 150 mg BID and £22,533/QALY for pregabalin 225 mg BID compared with placebo 53 . In the severe FM population, pregabalin 225 mg BID was also cost-effective compared with duloxetine 60 mg (ICER ¼ £19,224/ QALY) and 120 mg (ICER ¼ £14,096/QALY) and against gabapentin (ICER ¼ £35,737/QALY).…”

Section: Discussionmentioning

confidence: 99%

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

Lloyd

Boomershine

Choy

et al. 2012

Journal of Medical Economics

Self Cite

View full text Add to dashboard Cite

show abstract

Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective

Abstract: This model found pregabalin 300 mg and 450 mg to be cost effective compared with placebo and, within the limits of available evidence, against duloxetine using standard UK criteria in patients with fibromyalgia experiencing severe pain.

Cited by 19 publications

References 43 publications

Emerging Concepts in the Treatment of Myofascial Pain: A Review of Medications, Modalities, and Needle‐based Interventions

Emerging Concepts in the Treatment of Myofascial Pain: A Review of Medications, Modalities, and Needle‐based Interventions

Resource utilisation and direct costs in patients with recently diagnosed fibromyalgia who are offered one of three different interventions in a randomised pragmatic trial

The cost-effectiveness of pregabalin in the treatment of fibromyalgia: US perspective

Contact Info

Product

Resources

About